SCDM and ACRP Partner to Expand Services
The Society for Clinical Data Management and the Association of Clinical Research Professionals are pleased to announce a new collaboration that will help the organizations improve their support of professionals in clinical research.
“This is a natural relationship that makes sense for the members of both organizations,” said Ralph J. Russo, CCDM, chair of the SCDM Board of Trustees. “By providing events and educational opportunities across organizations, this agreement will foster innovation and synergy in the way data managers and other clinical professionals work together each day.”
Representing a combined 22,500 members worldwide, SCDM and ACRP share a common interest in promoting excellence among the various roles in clinical research. Collaborative efforts may include jointly-sponsored education programs, publication of best practices and cross-promotion of meetings and events.
“We are extremely excited to combine our efforts with SCDM,” said James D. Thomasell, CPA, ACRP executive director. “Our organizations are a natural fit both in terms of our missions and culture. We look forward to working closely with SCDM in advancing our missions and benefiting the clinical research enterprise.”
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
